Latest News and Press Releases

Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8...

Q1 2026 Gross Profit of $9.2 Million Increased $11.0 MillionQ1 2026 Net Income of $4.0 Million, or $0.05 per Share, Improved $16.0 Million Q1 2026 Adjusted EBITDA of $4.7 Million Improved $9.1 Million...

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22%...

Magnite Reports First Quarter 2026 Results

Increased Revenue by 10% Year-over-Year to $180.8 Million, Driven by Social and CTV Achieved Net Income of $6.4 Million and Adjusted EBITDA of $55.2 Million, representing a 31% Adjusted EBITDA...

Exceeds high end of first quarter guidance on revenue and profitability Raises 2026 revenue guidance to 15% year over year growth Highlights Revenue grew 20% year over year to $1.85 billion Product...

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2...

First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year...

RECORD QUARTER WITH 75.8% YEAR-OVER-YEAR REVENUE GROWTH HIGHLIGHTS IMPROVED OPERATING PERFORMANCE, DROVE RECORD REVENUES AND OPERATING INCOME, DELIVERING ADJUSTED EBITDA AND ADJUSTED DILUTED EPS...